Lineage Cell Therapeutics, Inc.
LCTX
$1.68
$0.074.35%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.78M | -30.46M | -4.14M | -3.27M | -3.03M |
| Total Depreciation and Amortization | 178.00K | 171.00K | 164.00K | 151.00K | 141.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.56M | 27.11M | -643.00K | -207.00K | 818.00K |
| Change in Net Operating Assets | -1.57M | -2.35M | -268.00K | -3.02M | -3.71M |
| Cash from Operations | -3.62M | -5.54M | -4.89M | -6.35M | -5.79M |
| Capital Expenditure | -12.00K | -14.00K | -97.00K | -365.00K | -112.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 0.00 | 2.00M | 3.00M | 4.00M |
| Cash from Investing | -12.00K | -14.00K | 1.90M | 2.64M | 3.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -16.00K | -14.00K | -14.00K | -14.00K | -13.00K |
| Issuance of Common Stock | 2.08M | -- | 5.30M | 21.81M | 10.00K |
| Repurchase of Common Stock | 0.00 | -65.00K | -15.00K | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -232.00K | -228.00K | -224.00K | -58.00K | -- |
| Cash from Financing | 1.83M | -307.00K | 5.04M | 21.73M | -3.00K |
| Foreign Exchange rate Adjustments | -4.00K | 293.00K | -73.00K | 25.00K | 38.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.80M | -5.57M | 1.99M | 18.05M | -1.86M |